NantKwest, Inc. (NASDAQ:NK) has received an average rating of “Hold” from the six research firms that are presently covering the company, Marketbeat reports. Three equities research analysts have rated the stock with a sell rating, two have given a hold rating and one has issued a buy rating on the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $5.33.

NK has been the topic of a number of research analyst reports. Citigroup Inc. set a $3.00 target price on NantKwest and gave the company a “sell” rating in a report on Monday, August 14th. Zacks Investment Research lowered NantKwest from a “buy” rating to a “hold” rating in a research report on Tuesday, May 30th. BidaskClub lowered NantKwest from a “hold” rating to a “sell” rating in a research report on Tuesday, August 8th. Finally, ValuEngine raised NantKwest from a “strong sell” rating to a “sell” rating in a research report on Wednesday, June 14th.

Shares of NantKwest (NASDAQ:NK) opened at 6.04 on Friday. NantKwest has a 12-month low of $4.35 and a 12-month high of $9.60. The stock’s market cap is $479.82 million. The company has a 50 day moving average price of $5.94 and a 200 day moving average price of $5.37.

COPYRIGHT VIOLATION WARNING: This news story was originally reported by American Banking News and is owned by of American Banking News. If you are viewing this news story on another site, it was illegally copied and republished in violation of international trademark and copyright laws. The correct version of this news story can be read at https://www.americanbankingnews.com/2017/09/16/nantkwest-inc-nk-receives-consensus-recommendation-of-hold-from-brokerages.html.

In other NantKwest news, Director Steve Gorlin sold 103,841 shares of the firm’s stock in a transaction dated Tuesday, September 12th. The stock was sold at an average price of $6.04, for a total value of $627,199.64. Following the transaction, the director now directly owns 375,002 shares of the company’s stock, valued at $2,265,012.08. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders sold 183,445 shares of company stock worth $1,173,251 over the last three months. 70.19% of the stock is currently owned by corporate insiders.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Goldman Sachs Group Inc. increased its position in shares of NantKwest by 0.5% during the first quarter. Goldman Sachs Group Inc. now owns 67,117 shares of the biotechnology company’s stock worth $238,000 after acquiring an additional 348 shares during the last quarter. New York State Common Retirement Fund increased its position in shares of NantKwest by 9.0% during the second quarter. New York State Common Retirement Fund now owns 19,400 shares of the biotechnology company’s stock worth $147,000 after acquiring an additional 1,599 shares during the last quarter. Wells Fargo & Company MN increased its position in shares of NantKwest by 13.0% during the second quarter. Wells Fargo & Company MN now owns 20,914 shares of the biotechnology company’s stock worth $158,000 after acquiring an additional 2,400 shares during the last quarter. Alliancebernstein L.P. increased its position in shares of NantKwest by 8.7% during the first quarter. Alliancebernstein L.P. now owns 33,800 shares of the biotechnology company’s stock worth $120,000 after acquiring an additional 2,700 shares during the last quarter. Finally, Nationwide Fund Advisors increased its position in shares of NantKwest by 67.6% during the second quarter. Nationwide Fund Advisors now owns 17,302 shares of the biotechnology company’s stock worth $131,000 after acquiring an additional 6,977 shares during the last quarter. 18.82% of the stock is currently owned by institutional investors and hedge funds.

NantKwest Company Profile

Receive News & Ratings for NantKwest Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NantKwest Inc. and related companies with MarketBeat.com's FREE daily email newsletter.